Anthrobots are microscopic, self-assembling biobots built from unmodified adult human cells. They move on their own, cluster at damaged tissue, and encourage it to heal — then quietly dissolve back into the body.
No metal, no chips, no code. An anthrobot is a small ball of living human airway cells that organizes itself and starts moving — a behavior discovered by researchers at Tufts University and the Wyss Institute at Harvard, building on earlier work with frog-cell "Xenobots."
Grown from tracheal (airway) cells taken from adult donor tissue — no embryos, no animal material, and no engineered DNA involved in making them move.
The same hair-like cilia that normally sweep mucus out of your lungs reorient outward on the bot's surface, beating in coordination to push it across a surface or through fluid.
Placed in the right culture conditions, the cells spontaneously round up and organize into a working, motile cluster — without a scaffold or external guidance.
These are the directions researchers are actively investigating. None are approved treatments yet — the value proposition is a bot that can be steered toward a specific problem, do one job, and leave.
In lab tests, clusters of anthrobots gathered along a "wound" scratched into a layer of human neurons and promoted dense regrowth across the gap — without any genetic modification to trigger it.
A proposed use in atherosclerosis: bots that travel through vessels and physically or chemically help break down plaque buildup at the site, rather than treating the whole circulatory system.
Because they're built from airway cells with working cilia, one proposed direction is helping move excess mucus out of the lungs of patients with conditions like cystic fibrosis.
Rather than a pill that circulates everywhere, a bot could theoretically carry and release a therapeutic payload only where it's needed — reducing whole-body side effects.
Researchers envision future versions engineered to detect and flag abnormal or bacterial cells, acting as roaming sensors inside tissue.
A biotech partner on the original research has floated applying the same clustering-and-healing effect to burns and other slow-healing wounds.
A treatment made from a donor's own tissue doesn't read as foreign to their immune system. That single fact removes two of the biggest costs of many current cell-based therapies: rejection risk, and the lifelong medication needed to prevent it.
It also opens the door to something closer to a personalized prescription — a batch of bots grown specifically from one patient's cells, sized and directed for their case.
A therapy that can't outstay its welcome is easier to trust. Anthrobots don't reproduce and aren't genetically altered, so there's no path for them to evolve, spread, or persist beyond their working window.
A 2025 study tracking the full life cycle of anthrobots — from assembly to natural breakdown — turned up two findings that matter for future therapies.
Reduction in epigenetic age measured in cells after they assemble into an anthrobot, compared with their starting state — a marker usually associated with cellular aging running in reverse.
Adv. Science, 2025The bots themselves showed a capacity to repair damage to their own structure, a property that could make therapeutic batches more durable and consistent to work with.
Adv. Science, 2025Because anthrobots come from adult airway cells rather than embryonic tissue and don't include neural tissue, researchers point to this as easing some of the ethical questions raised by other organoid research.
Adv. Science, 2025